Why Your Body Destroys NAD+ Before It Can Use It (And the $5 Fix Nobody Talks About)

Your body cannot use NAD+ directly. The molecule is too large to pass through a cell membrane, so no matter how much NAD+ you put into your bloodstream, whether through a supplement or an IV drip, it never actually enters the cell intact.

What happens instead is that your body breaks NAD+ down into smaller components outside the cell, those components cross the membrane, and then the cell reassembles them back into NAD+ on the inside. This reassembly process is called the salvage pathway, and it is the central mechanism that almost every NAD+ supplement on the market is trying to work with.

This is where it gets important to understand the full chain before we talk about anything else.

NMN, which is nicotinamide mononucleotide, is one of the most popular and expensive NAD+ precursors available. The idea behind taking it is that it is one step away from NAD+ in the synthesis chain, so it should be efficient. And for a while, that logic seemed sound. But a 2016 study published in Nature Communications found that NMN cannot actually enter cells directly either. An enzyme called CD73 has to convert NMN into something called NR, which is nicotinamide riboside, before any of it can be transported inside. So when you take NMN, you are essentially paying for something that has to become NR before it can do anything at all.

That means NMN and NR both funnel through the same entry point, and both rely on the same salvage pathway once they are inside the cell.

So what is wrong with the salvage pathway? On its own, nothing. The problem is what happens to that pathway as you age.

There is an enzyme called CD38, and its job is to consume NAD+. It is part of your immune signaling system and it is supposed to be there, but research published in Cell Metabolism in 2016 found that CD38 activity increases two to three fold across tissues as you get older, and there is a near-perfect inverse relationship between how active CD38 is and how much NAD+ you have. As CD38 goes up, NAD+ comes down. This is one of the main reasons NAD+ levels decline so sharply with age. The salvage pathway is still running, but CD38 is chewing through the output faster than the pathway can keep up.

This is the bottleneck that most NAD+ supplements are trying to overcome. You are pouring NMN or NR into a pathway that is under increasing pressure from the other direction, and you are hoping supply can outpace consumption.

That might work to some degree. But there is a completely separate pathway for producing NAD+ that bypasses CD38's primary zone of activity entirely.

It is called the Preiss-Handler pathway, and it is activated by niacin, which is just the common name for vitamin B3 in its nicotinic acid form. Niacin does not enter through the same cellular machinery as NR. It uses a different transporter, feeds into a different synthesis chain, and produces NAD+ through a route that the salvage pathway congestion does not affect in the same way.

A 2020 study published in Cell Metabolism looked at patients with adult-onset mitochondrial myopathy, a condition that causes confirmed systemic NAD+ deficiency, and gave them niacin at doses between 750 and 1000 milligrams per day. After ten months, blood NAD+ levels had risen 2.3 times from baseline. Muscle NAD+ went up 1.3 times. Muscle strength improved and the researchers also saw signs of mitochondrial biogenesis, meaning the cells were building new mitochondria in response to the increased NAD+ availability.

That 2.3 times increase in blood NAD+ is in the same range as what studies on NMN and NR have reported, and it was achieved through a separate pathway that does not face the same age-related congestion problem.

There is also an interesting finding from a 2019 study in Cell Reports that adds a wrinkle to this whole picture. When researchers looked at what NR supplementation was actually doing inside aged human muscle, they found significant increases in something called NAAD, which is an intermediate in the Preiss-Handler pathway. This suggests that a portion of the NR people take is actually converting into nicotinic acid in the body and feeding into the Preiss-Handler pathway anyway, not just the salvage pathway. So even the expensive precursors may be working partly through the same mechanism as niacin, at a much higher price per dose.

The practical consideration with niacin is the flush. Nicotinic acid causes prostaglandin-mediated vasodilation, which means the blood vessels near the surface of your skin widen and you get a warm, red, itchy sensation across your face, chest, and arms. It is harmless and it typically fades within the first one to two weeks of consistent use as your body adapts. Starting at a lower dose and taking it with food reduces the intensity. This is not a side effect that indicates anything is going wrong. It is just a direct pharmacological effect of the molecule.

Niacin in plain nicotinic acid form is available at any pharmacy for roughly five dollars a month. The extended-release prescription form called niaspan has been associated with liver stress at therapeutic doses, but plain immediate-release nicotinic acid at the doses used in the research does not carry that same concern.

The deeper point here is not that NMN and NR do not work. The research suggests they do something. The point is that the logic of paying a premium for a precursor because it is closer to NAD+ in the synthesis chain falls apart once you understand that the chain has a bottleneck, and that there is a second road into the same destination that most people have never been told about.

Your cells have been making NAD+ from niacin for as long as humans have existed. The Preiss-Handler pathway was not discovered by the supplement industry, and it cannot be patented. That is probably the most important fact about it.

---

References

1. Ratajczak J, Joffraud M, Trammell SAJ, et al. 2016. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications, 7:13103. Finding: NMN must be converted to NR by CD73 before cellular uptake, establishing NR as the common entry point for both NMN and NR supplementation. Source
2. Elhassan YS, Kluckova K, Fletcher RS, et al. 2019. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 287:1717-1728. Finding: NR supplementation produced significant increases in NAAD a Preiss-Handler pathway intermediate in human muscle, indicating NR partially converts to nicotinic acid in vivo. Source
3. Pirinen E, Auranen M, Khan NA, et al. 2020. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 316:1078-1090. Finding: Niacin 750-1000 mg/day raised blood NAD+ 2.3x and muscle NAD+ 1.3x in human subjects via the Preiss-Handler pathway, with concurrent improvements in muscle strength and mitochondrial biogenesis. Source
4. Grant R, Berg J, Mestayer R, et al. 2019. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 11:257. Finding: IV NAD+ 750 mg was rapidly and completely removed from plasma, with metabolites confirming full extracellular degradation before cellular uptake. Source
5. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. 2016. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 236:1127-1139. Finding: CD38 activity increases 2-3 fold with age across tissues, with near-perfect inverse correlation to NAD+ levels. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness